This stock is no longer traded. It was delisted on July 9, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Zyversa Therapeutics Inc. is a clinical-stage pharmaceutical company primarily focused on the development of drug candidates targeting unmet medical needs in inflammatory and renal diseases. The company's key function is to advance its pipeline of therapies, particularly those addressing chronic kidney disease and inflammatory conditions. Zyversa's approach involves innovative treatments that aim to modulate the body's immune and inflammatory responses. One of the notable aspects of Zyversa is its commitment to addressing significant health challenges that have limited treatment options, thereby impacting a wide array of patients and the healthcare industry at large. Zyversa holds a strategic position in the biotech sector, leveraging its scientific expertise to collaborate with researchers and institutions to drive progress in its therapeutic areas. By concentrating on two critical and often overlapping fields—immunology and nephrology—Zyversa plays a crucial role in the pharmaceutical markets' ever-growing demand for specialized and effective treatment solutions.
Website2200 N. Commerce Parkway
Weston, FL, 33326
United States
Summary of Jul 16's posts. Generated by AI.
Summary of Jul 8's posts. Generated by AI.
Summary of Sep 14's posts. Generated by AI.
Investors talking about ZVSA also mention these. Each card shows that asset’s own numbers for the past 24 hours.